Pembrolizumab-话题@MedSci

#Pembrolizumab#

99篇内容 | 3842人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2196918, encodeId=ae0f21969187b, content=<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a> <a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Lancet：Pembrolizumab联合化放疗治疗新诊断的局部晚期宫颈癌可显著改善无进展生存期, objectType=article, longId=820311, objectId=ca0d8203114d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301012/1697149335278_4754896.jpeg, objectUrl=/article/show_article.do?id=ca0d8203114d, replyNumber=0, likeNumber=82, createdTime=2024-04-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ca0d8203114d, moduleTitle=Lancet：Pembrolizumab联合化放疗治疗新诊断的局部晚期宫颈癌可显著改善无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0d8203114d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2192006, encodeId=6285219200651, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=European Radiology:pembrolizumab联合化疗治疗的晚期非小细胞肺癌的价值及评估, objectType=article, longId=816345, objectId=e2dc8163459c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240307/1709823684531_1605392.png, objectUrl=/article/show_article.do?id=e2dc8163459c, replyNumber=0, likeNumber=0, createdTime=2024-03-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e2dc8163459c, moduleTitle=European Radiology:pembrolizumab联合化疗治疗的晚期非小细胞肺癌的价值及评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2dc8163459c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183677, encodeId=cb2321836e73b, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a> <a href='/topic/show?id=e38e100121c7' target=_blank style='color:#2F92EE;'>#顺铂化疗#</a> <a href='/topic/show?id=bb5a1104e28e' target=_blank style='color:#2F92EE;'>#肌层浸润性尿路上皮膀胱癌#</a>, objectTitle=Eur Urol Oncol：肌层浸润性尿路上皮膀胱癌患者中新辅助 Pembrolizumab 与顺铂化疗或前期根治性膀胱切除术的疗效比较, objectType=article, longId=810785, objectId=6b1e810e85e6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240124/1706071938697_1935437.jpg, objectUrl=/article/show_article.do?id=6b1e810e85e6, replyNumber=0, likeNumber=87, createdTime=2024-01-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6b1e810e85e6, moduleTitle=Eur Urol Oncol：肌层浸润性尿路上皮膀胱癌患者中新辅助 Pembrolizumab 与顺铂化疗或前期根治性膀胱切除术的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1e810e85e6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183453, encodeId=cc1d218345337, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a> <a href='/topic/show?id=75d25989596' target=_blank style='color:#2F92EE;'>#晚期食管癌#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=ASCO GI 2024：一线pembrolizumab+化疗治疗晚期食管癌：3期KEYNOTE-590研究的5年结果 , objectType=article, longId=810642, objectId=005881064236, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=005881064236, replyNumber=0, likeNumber=71, createdTime=2024-01-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=005881064236, moduleTitle=ASCO GI 2024：一线pembrolizumab+化疗治疗晚期食管癌：3期KEYNOTE-590研究的5年结果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005881064236)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183153, encodeId=5fdc2183153bb, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a> <a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=ASCO GI 2024：pembrolizumab联合FLOT与单纯FLOT作为局部晚期胃癌和胃食管交界处癌的新辅助和辅助治疗：KEYNOTE-585研究3期中期分析, objectType=article, longId=810454, objectId=91158104547c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=91158104547c, replyNumber=0, likeNumber=83, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=91158104547c, moduleTitle=ASCO GI 2024：pembrolizumab联合FLOT与单纯FLOT作为局部晚期胃癌和胃食管交界处癌的新辅助和辅助治疗：KEYNOTE-585研究3期中期分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91158104547c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2170533, encodeId=018f21e053327, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a> <a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a> <a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Eur Urol Oncol：Pembrolizumab和Enzalutamide在已经使用醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者中的效果如何？, objectType=article, longId=801828, objectId=d50c801828b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231122/1700624702069_1935437.jpg, objectUrl=/article/show_article.do?id=d50c801828b3, replyNumber=0, likeNumber=69, createdTime=2023-11-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d50c801828b3, moduleTitle=Eur Urol Oncol：Pembrolizumab和Enzalutamide在已经使用醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者中的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50c801828b3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2166299, encodeId=5999216629922, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a> 与 <a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>联合治疗 <a href='/topic/show?id=c0591168658' target=_blank style='color:#2F92EE;'>#MIBC#</a> 具有可行性，且毒性可控，且CR率前景看好。, objectTitle=Eur Urol Oncol：Pembrolizumab 联合化放疗治疗肌层浸润性膀胱癌： PCR-MIB 2期临床试验（ANZUP 1502）中的安全性和有效性分析, objectType=article, longId=798945, objectId=7267e989459a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231102/1698895354043_1935437.jpg, objectUrl=/article/show_article.do?id=7267e989459a, replyNumber=0, likeNumber=0, createdTime=2023-11-02, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7267e989459a, moduleTitle=Eur Urol Oncol：Pembrolizumab 联合化放疗治疗肌层浸润性膀胱癌： PCR-MIB 2期临床试验（ANZUP 1502）中的安全性和有效性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7267e989459a)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2131311, encodeId=ec942131311a6, content=<a href='/topic/show?id=2ca46852d7' target=_blank style='color:#2F92EE;'>#Epacadostat#</a>+ <a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>治疗晚期<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>可使ORR和疾病控制率分别达到35%和63%；去年9月的ESMO2017大会上Incyte宣布I/II期ECHO-202（KEYNOTE-037）研究中epacadostat+ pembrolizumab可使晚期<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>患者的ORR达到56%；去年11月BMS公布的Opdivo联合自家<a href='/topic/show?id=9517942978' target=_blank style='color:#2F92EE;'>#IDO抑制剂#</a><a href='/topic/show?id=6cd310620285' target=_blank style='color:#2F92EE;'>#BMS-986205#</a>的I/II期研究中，<a href='/topic/show?id=843a85e9421' target=_blank style='color:#2F92EE;'>#膀胱癌#</a>和<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a>队列患者也取得了积极结果。但三期失败，不过，最近文献来看，在<a href='/topic/show?id=01858406438' target=_blank style='color:#2F92EE;'>#胶质母细胞瘤#</a>可能<a href='/topic/show?id=2853942e78' target=_blank style='color:#2F92EE;'>#IDO1#</a>仍然有相当的潜力！！, objectTitle=ECHO-301意外失败：IDO抑制剂类肿瘤免疫抑制剂路在何方？, objectType=article, longId=134457, objectId=46d813445ec7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201804/20180407094338753.JPEG, objectUrl=/article/show_article.do?id=46d813445ec7, replyNumber=0, likeNumber=134, createdTime=2023-05-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=46d813445ec7, moduleTitle=ECHO-301意外失败：IDO抑制剂类肿瘤免疫抑制剂路在何方？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46d813445ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2131310, encodeId=1477213131098, content=<a href='/topic/show?id=2ca46852d7' target=_blank style='color:#2F92EE;'>#Epacadostat#</a>是一种有效且高度选择性的<a href='/topic/show?id=2853942e78' target=_blank style='color:#2F92EE;'>#IDO1#</a>酶抑制剂。<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>是一种PD1抑制剂。ECHO-202 / KEYNOTE-037试验评估了epacadostat联合pembrolizumab治疗晚期<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>患者的效果，可惜3期失败, objectTitle=JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤, objectType=article, longId=150031, objectId=8f8f1500318b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201809/20180929162041452.jpg, objectUrl=/article/show_article.do?id=8f8f1500318b, replyNumber=0, likeNumber=0, createdTime=2023-05-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8f8f1500318b, moduleTitle=JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8f1500318b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272586, encodeId=dbed12e25869e, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较, objectType=article, longId=736966, objectId=ac21e36966ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac21e36966ab, replyNumber=0, likeNumber=90, createdTime=2022-08-27, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac21e36966ab, moduleTitle=Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac21e36966ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272585, encodeId=e9b312e258519, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, objectType=article, longId=726424, objectId=b321e2642494, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b321e2642494, replyNumber=0, likeNumber=96, createdTime=2022-05-10, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b321e2642494, moduleTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b321e2642494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272584, encodeId=f75f12e25849c, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, objectType=article, longId=724681, objectId=ae69e2468173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae69e2468173, replyNumber=0, likeNumber=89, createdTime=2022-04-22, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae69e2468173, moduleTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae69e2468173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272583, encodeId=308c12e2583d1, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=134, createdTime=2022-03-28, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272582, encodeId=279b12e25826e, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=95, createdTime=2022-03-21, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272581, encodeId=268512e25813b, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, objectType=article, longId=295254, objectId=ccd329525402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd329525402, replyNumber=0, likeNumber=56, createdTime=2022-02-09, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd329525402, moduleTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccd329525402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272580, encodeId=680912e2580f2, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, objectType=article, longId=294454, objectId=3f302944546a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f302944546a, replyNumber=0, likeNumber=63, createdTime=2022-01-23, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f302944546a, moduleTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f302944546a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272579, encodeId=792712e2579d1, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, objectType=article, longId=293562, objectId=0e1f293562ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1f293562ed, replyNumber=0, likeNumber=90, createdTime=2022-01-09, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1f293562ed, moduleTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e1f293562ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272578, encodeId=9b3612e257873, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法, objectType=article, longId=292248, objectId=3be42922488a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3be42922488a, replyNumber=0, likeNumber=77, createdTime=2021-12-21, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3be42922488a, moduleTitle=NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3be42922488a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272577, encodeId=313112e257792, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效, objectType=article, longId=221635, objectId=7c93221635a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c93221635a0, replyNumber=0, likeNumber=79, createdTime=2021-12-08, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c93221635a0, moduleTitle=Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c93221635a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1272576, encodeId=2c2f12e2576e1, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=221052, objectId=063622105235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063622105235, replyNumber=0, likeNumber=82, createdTime=2021-11-27, rootId=0, userName=hxj0117, userId=ac59108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063622105235, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=063622105235)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Pembrolizumab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#宫颈癌# #Pembrolizumab#

Lancet：Pembrolizumab联合化放疗治疗新诊断的局部晚期宫颈癌可显著改善无进展生存期

2024-04-04发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #Pembrolizumab#

European Radiology:pembrolizumab联合化疗治疗的晚期非小细胞肺癌的价值及评估

2024-03-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#Pembrolizumab# #顺铂化疗# #肌层浸润性尿路上皮膀胱癌#

Eur Urol Oncol：肌层浸润性尿路上皮膀胱癌患者中新辅助 Pembrolizumab 与顺铂化疗或前期根治性膀胱切除术的疗效比较

2024-01-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#Pembrolizumab# #晚期食管癌# #ASCO GI 2024#

ASCO GI 2024：一线pembrolizumab+化疗治疗晚期食管癌：3期KEYNOTE-590研究的5年结果

2024-01-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期胃癌# #Pembrolizumab# #ASCO GI 2024#

ASCO GI 2024：pembrolizumab联合FLOT与单纯FLOT作为局部晚期胃癌和胃食管交界处癌的新辅助和辅助治疗：KEYNOTE-585研究3期中期分析

2024-01-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#前列腺癌# #Enzalutamide# #Pembrolizumab#

Eur Urol Oncol：Pembrolizumab和Enzalutamide在已经使用醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者中的效果如何？

2023-11-23发表于上海

(审核中...)

前往app查看评论内容

#Pembrolizumab# 与 #CRT#联合治疗 #MIBC# 具有可行性，且毒性可控，且CR率前景看好。

Eur Urol Oncol：Pembrolizumab 联合化放疗治疗肌层浸润性膀胱癌： PCR-MIB 2期临床试验（ANZUP 1502）中的安全性和有效性分析

2023-11-02发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

全文收起 #Epacadostat#+ #Pembrolizumab#治疗晚期#NSCLC#可使ORR和疾病控制率分别达到35%和63%；去年9月的ESMO2017大会上Incyte宣布I/II期ECHO-202（KEYNOTE-037）研究中epacadostat+ pembrolizumab可使晚期#黑色素瘤#患者的ORR达到56%；去年11月BMS公布的Opdivo联合自家#IDO抑制剂##BMS-986205#的I/II期研究中，#膀胱癌#和#宫颈癌#队列患者也取得了积极结果。但三期失败，不过，最近文献来看，在#胶质母细胞瘤#可能#IDO1#仍然有相当的潜力！！

ECHO-301意外失败：IDO抑制剂类肿瘤免疫抑制剂路在何方？

2023-05-10发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#Epacadostat#是一种有效且高度选择性的#IDO1#酶抑制剂。#Pembrolizumab#是一种PD1抑制剂。ECHO-202 / KEYNOTE-037试验评估了epacadostat联合pembrolizumab治疗晚期#实体瘤#患者的效果，可惜3期失败

JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤

2023-05-10发表于上海

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较

2022-08-27

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效

2022-05-10

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果

2022-04-22

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-03-28

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2022-03-21

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效

2022-02-09

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究

2022-01-23

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著

2022-01-09

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法

2021-12-21

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效

2021-12-08

hxj0117 (审核中...)

前往app查看评论内容

#Pembrolizumab#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2021-11-27

科室
- - 订阅+
  - 更多科室
工具
服务